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Objective: Preeclampsia is a complex heterogeneous
disease commonly defined by new-onset hypertension
and proteinuria in pregnancy. Women experiencing
preeclampsia have increased risk for cardiovascular
diseases (CVD) later in life. Preeclampsia and CVD share
risk factors and pathophysiologic mechanisms,
including dysregulated inflammation and raised blood
pressure. Despite commonalities, little is known
about the contribution of shared genes (pleiotropy) to
these diseases. This study aimed to investigate
whether genetic risk factors for hypertension or
inflammation are pleiotropic by also being associated
with preeclampsia.

Abbreviations: AGER, advanced glycosylation end
product-specific receptor; ATP2B1, ATPase Ca2þ
transporting, plasma membrane 1; BP, blood pressure; CI
95%, 95% confidence interval; CVD, cardiovascular
diseases; ENCODE, Encyclopedia of DNA Elements; eQLTs,
expression quantitative trait loci; GTEx, Genotype-Tissue
Expression Project; GWAS, genome-wide association
studies; HUNT, the HUNT Study; LD, linkage disequilibrium;
MAF, minor allele frequency; MBRN, Medical Birth Registry
of Norway; MTHFR, methylenetetrahydrofolate reductase;
NHGRI Catalog, National Human Genome Research
Institute Catalog of Published Genome-Wide Association
Studies; NLRP, NOD-like receptor containing pyrin domain;
NOD, nucleotide-binding oligomerization domain; OR,
odds ratio; PAX5, paired box 5; PheGenI, phenotype–
genotype integrator; PLCD3, phospholipase C delta 3;
RGS, regulator of G-protein signaling; SNP, single
nucleotide polymorphism; TLR, Toll-like receptor; VEGF,
vascular endothelial growth factor

Methods: We genotyped 122 single nucleotide
polymorphisms (SNPs) in women with preeclampsia
(n ¼ 1006) and nonpreeclamptic controls (n ¼ 816) from
the Norwegian HUNT Study. SNPs were chosen on the
basis of previously reported associations with either
nongestational hypertension or inflammation in genomewide association studies. The SNPs were tested for
association with preeclampsia in a multiple logistic
regression model.
Results: The minor (G) allele of the intronic SNP
rs17367504 in the gene methylenetetrahydrofolate
reductase (MTHFR) was associated with a protective effect
on preeclampsia (odds ratio 0.65, 95% confidence interval
0.53–0.80) in the Norwegian cohort. This association did
not replicate in an Australian preeclampsia case–control
cohort (P ¼ 0.68, odds ratio 1.05, 95% confidence interval
0.83–1.32, minor allele frequency ¼ 0.15).
Conclusion: MTHFR is important for regulating
transmethylation processes and is involved in regulation of
folate metabolism. The G allele of rs17367504 has
previously been shown to protect against nongestational
hypertension. Our study suggests a novel association
between this allele and reduced risk for preeclampsia. This
is the first study associating the minor (G) allele of a SNP
within the MTHFR gene with a protective effect on
preeclampsia, and in doing so identifying a possible
pleiotropic protective effect on preeclampsia and
hypertension.
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INTRODUCTION

P

reeclampsia is a disease of pregnancy with potentially severe and fatal outcomes for mother and fetus.
The condition occurs in 2–8% of pregnancies and is
commonly defined as de novo hypertension and proteinuria
after gestational week 20 [1]. Women who experience
preeclampsia have a two to eight-fold increased risk of
subsequent development of cardiovascular diseases (CVD)
[2], a major cause of death in women worldwide [3].
Preeclampsia and CVD share lifestyle-related, pathophysiological, and genetic risk factors [4–10]. For the joint
pathophysiologic mechanisms, genetic and molecular functional studies have demonstrated endothelial dysfunction,
inflammation, and vascular remodeling to be crucial to the
development of chronic hypertension [9,10]. Changes in
these biological processes are also thought to play a role in
preeclampsia [11]. Aberrant blood pressure (BP) regulation
can lead to sustained hypertension and CVD in susceptible
individuals [12]. Hypertension developing during pregnancy (gestational hypertension) is the only consistent part
of the preeclampsia diagnosis included in all definitions
of the disease, whereas other diagnostic criteria of the
disorder, including proteinuria, have varied between populations and over time [1,13–15]. Both gestational and nongestational hypertension are usually defined by BP at least
140/90 mmHg, but it is not known whether these two
conditions share a common cause. Preeclampsia as well
as CVD involves release of angiogenic factors, oxidative
stress, and adaptive metabolic changes like hyperlipidemia
and increased insulin resistance, resulting in sustained
inflammation and endothelial dysfunction [10,16]. The
physiologic low-grade systemic inflammation of pregnancy
is dysregulated and enhanced in preeclampsia at the
maternal–fetal interface in the oxidatively stressed placenta
and in the maternal vascular system [16,17]. In CVD periods
of reduced tissue perfusion and ischemia with subsequent
tissue reperfusion increase the level of cellular oxidative
stress and thereby establish a sustained inflammatory
response locally in tissues and generalized in the circulatory
system [9,10].
The genetic contributions to preeclampsia and CVD
have been established separately in large cohorts based
on national registries and longitudinal health surveys as
well as through family studies [4–7,18,19]. The maternal
heritability estimates for preeclampsia are in the range
35–60% [6,19], whereas the heritability of BP regulation
is estimated to 16–63% [4–7,19]. Genome-wide association
studies (GWAS) on either preeclampsia or BP regulation
have identified genetic variants associated with each of
these conditions. The first GWAS published on preeclampsia identified two loci near the Inhibin beta B gene that
could not be replicated in two other cohorts, whereas the
second GWAS had a smaller numbers of cases and did not
find any genome-wide significant associations [20,21]. Large
GWAS have identified several genetic loci associated with
BP regulation [22–30] and other inflammatory diseases such
as inflammatory bowel disease, diabetes mellitus type 2,
and lung function [31–33].
The concept of pleiotropy is receiving increasing attention in studies on complex diseases. Pleiotropy concerns
Journal of Hypertension

how a single genetic variant directly regulates the expression of two or more phenotypes, either by inducing the
same biological effect on two phenotypes or influencing
opposite phenotypic effects through inducing both a
protective and a disease promoting phenotype [34,35].
GWAS have resulted in identification of single nucleotide
polymorphisms (SNPs) in genetic regions significantly
associated with several seemingly unrelated conditions,
indicating presence of pleiotropic influences on the development of complex human conditions. Despite an increasing awareness of a pathophysiologic relationship between
preeclampsia and chronic hypertension, both risk factors
for CVD, few studies have investigated possible
pleiotropic genetic effects on these conditions or focused
on their shared pathophysiological mechanisms of disease
development [36–39].
In this study, our aim was to test the association between
122 SNPs previously associated with the phenotypes BP
regulation and inflammation with preeclampsia. These
phenotypes were chosen on the basis of their prominent
involvement in both CVD and preeclampsia.

METHODS
Ethics statement
The Norwegian Regional Committees for Medical and
Health Research Ethics (REK 2012/1876) and the HUNT
Research Centre (HUNT 13/4894) have approved the project. Informed consent was obtained from all participants
when enrolled in the HUNT surveys.
The Australian study was approved by the Royal Women’s Hospital Research and Ethics Committees, Melbourne,
Australia, and the Institutional Review Board of the University of Texas Health Science Center at San Antonio, San
Antonio, Texas, USA. All study participants gave their
written informed consent when enrolled in the study.

Study population
In this report, the HUNT Study (HUNT), a longitudinal
health study containing a biorepository, was linked to
the Medical Birth Registry of Norway (MBRN) to identify
female HUNT participants who had been diagnosed with
preeclampsia and a control group with unaffected
pregnancies.

The Medical Birth Registry of Norway
The MBRN is a national databank based on unique identification numbers and compulsory notification that contains
information collected since 1967 on all pregnancies in
Norway of at least 16 weeks gestation. The registered data
detail maternal health before and during pregnancy, complications during pregnancy and delivery, and pregnancy
outcomes [40].

The HUNT Study
The HUNT Study is a collaboration between the HUNT
Research Centre (Faculty of Medicine, Norwegian University of Science and Technology), Nord-Trøndelag County
Council, the Central Norway Health Authority, and the
Norwegian Institute of Public Health. The HUNT Study
www.jhypertension.com
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consists of three separate multipurpose health surveys
(HUNT1–3) in the adult population of Nord-Trøndelag
County in Norway and has been described in detail elsewhere [41,42]. The ethnicity of participants is not requested
in the surveys, but the population in Nord-Trøndelag is
stable and ethnically homogenous with more than 97% of
Northern European origin. The main purpose of the HUNT
Study is to investigate etiological factors of human disease.
The three parts of the study took place in 1984–1986
(HUNT1), 1995–1997 (HUNT2), and 2006–2008 (HUNT3),
and the available data on participants consist of health
information based on questionnaires and physical examinations, as well as biological samples from individuals
taking part in HUNT2 and HUNT3. Approximately 41,500
women participated and donated biological samples in
at least one part of the study. Of these, over 20,000
women took part in both HUNT2 and HUNT3, and about
15,300 women participated in all three surveys (http://
www.ntnu.no/hunt/oppmote, accessed 11 May 2015).

Data linkage
By means of the unique national identification numbers,
data from the MBRN have been linked with the HUNT
Databank to identify a preeclampsia case–control cohort of
female participants in HUNT2 and HUNT3. These women
gave birth between 1967 and 2009 and have pregnancies
registered in the MBRN either with preeclampsia (cases) or
as having had only pregnancies unaffected by preeclampsia, gestational hypertension, and chronic hypertension
(controls).

The Australian preeclampsia case–control
cohort
The replication cohort from Australia has previously
been described [20]. Briefly, 1092 women (545 preeclampsia cases and 547 controls) of European ancestry were
recruited at the Royal Women’s Hospital, Melbourne,
Australia. Of the 1092 individuals included 1018 women
(471 preeclampsia cases and 547 controls) were ascertained
from a larger case–control cohort assembled over a 5-year
period (2007–2011), and an additional 74 unrelated preeclampsia cases were from a family-based cohort recruited
over a 15-year period (1984–1999) [43].

Clinical definition of phenotypes
Data on gestational health and outcomes from the MBRN
and well defined clinical and laboratory information from
the HUNT Databank were used to identify phenotypes and
covariates related to preeclampsia. Time of participation in
HUNT was not related in time to the pregnancies and births
of the included women.
Data from the MBRN contained information on all pregnancies and births of each woman, including maternal
health prior to and during the pregnancies. For the women
who had participated in more than one HUNT survey, all
available relevant information was utilized, including data
on diabetes, asthma, inflammatory diseases, use of medication, risk factors of CVD, established CVD and family
history of CVD, as well as BP measurements and results
from biochemical blood analysis.
134
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In the MBRN preeclampsia is registered according
to the set criteria of the repository: hypertension
(BP  140/90 mmHg) with proteinuria (þ1 protein on a
urine dipstick). We have previously found the diagnostic
validity of these criteria to be 88.3% when examined against
medical records of women in HUNT who gave birth at two
hospitals (Levanger Hospital and Namsos Hospital) [15].
Cases and controls lacking phenotypic information on
pregnancies and births in the MBRN were excluded. Individuals originally selected as controls were omitted if they
had any pregnancies registered in the MBRN as stillbirths or
complicated by placental abruption, or if they, prior to
pregnancy, had an established kidney disorder, maternal
heart disease, or a chronic inflammatory disorder such as
rheumatoid arthritis. Numbers for excluded cases and controls can be found in SDC2 Table 2, http://links.lww.com/
HJH/A681 in Supplemental digital content.
In the Australian cohort preeclampsia was defined as de
novo hypertension with proteinuria after 20 weeks of
gestation. Hypertension was defined as BP at least
140/90 mmHg or, an increase in SBP and/or DBP of at least
25 and/or 15 mmHg, respectively. Proteinuria was defined
as either at least 0.3 g/l in a 24-h urine specimen, at least a
‘2þ’ dipstick reading from a random urine sample, or a
spot protein : creatinine ratio at least 0.03 g/mmol. The
preeclampsia diagnosis was determined by clinicians examining information in the medical hospital records of the
participant. Exclusion criteria were preexisting hypertension or other medical conditions known to predispose for
preeclampsia such as renal disease and diabetes mellitus.
Further, women pregnant with twins or fetuses with chromosomal abnormalities were excluded.

Genotyping and quality control
Single nucleotide polymorphism selection
The SNP selection was based on results from GWAS performed in populations of European descent to match our
study cohort. The studies were registered in one of two
databases: the National Human Genome Research Institute
Catalog of Published Genome-Wide Association Studies
(NHGRI Catalog), containing published GWAS data [44],
and the NCBI resource phenotype–genotype integrator
(PheGenI) [45]. PheGenI contains genetic results assembled
from several sources and by several methods, including
published and unpublished raw data from GWAS. In the
NHGRI Catalog (http://www.genome.gov/gwastudies/,
accessed 25 February 2013), we utilized search filters ‘blood
pressure’ and ‘hypertension’ as well as P value 106 or less,
at which point 87 SNPs mapped to 65 unique genic regions
were reported at this P value.
We next applied the following inflammatory genes one
by one as filters in the PheGenI (http://www.ncbi.nlm.nih.gov/gap/phegeni, accessed 25 March 2013) including
only results with P value 106 or less: Toll-like receptor
(TLR) 1, TLR2, TLR3, TLR4, TLR5, TLR9, nucleotide-binding
oligomerization domain (NOD) 1, NOD2, advanced glycosylation end product-specific receptor (AGER), NODlike receptor containing pyrin domain (NLRP)3, NLRP12,
vascular endothelial growth factor A (VEGF)-A, VEGF-B,
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regulator of G-protein signaling 5 (RGS5), and NLR family
CARD domain-containing protein 4 (NLRC4). For 10 of
these genes, GWA results below the set P value were
identified: TLR1, TLR4, TLR5, NOD1, NOD2, AGER, NLRP3,
NLRP12, VEGF-A, and RGS5, resulting in n ¼ 163 inflammatory SNPs for replication.
Of the in total 250 identified SNPs, 61 were found in
duplicate and 74 were in linkage disequilibrium with
another SNP in the dataset (SNAP [46] r2  0.8, HapMap
release 21, Northern Europeans from Utah population). The
SNP with the highest rs-number in each linkage disequilibrium pair was excluded, leaving 115 SNPs for genotyping
(SDC1 Table 1, http://links.lww.com/HJH/A681).
Genotyping
DNA was extracted by the HUNT Biobank from whole
blood or blood clots sampled at inclusion in the HUNT2
and HUNT3 and stored at the HUNT Biobank, Levanger,
Norway [41,42]. The genotyping was performed on the
Sequenom MassARRAY system (Sequenom iPLEXassay,
Sequenom Inc., San Diego, California, USA) by the Australian Genome Research Facility Ltd., St Lucia, Queensland, Australia. Of the 115 SNPs, 12 failed designability,
11 of which were replaced by all suitable surrogates
(r2 ¼ 1). Finally a total of 122 SNPs were successfully genotyped, effectively covering 114 of the 115 SNPs originally
planned genotyped.
Quality control
Standard quality control methods were applied as
described in Supplementary material SDC2 Table 2,
http://links.lww.com/HJH/A681 and SDC3 Table 3,
http://links.lww.com/HJH/A681. Of 2187 samples genotyped, we excluded 125 individuals with very low quality
DNA who failed all genotyping assays. From the remaining
samples only individuals with average call rates more than
95% were included in the genetic analysis (SDC2 Table 2,
http://links.lww.com/HJH/A681). SNPs failing genotyping
and SNPs with call rates less than 98% were excluded from
further analysis (SDC3 Table 3, http://links.lww.com/HJH/
A681). Of the 122 SNPs successfully genotyped in the
cohort, 119 SNPs passed the quality control and were
analyzed in the 1822 individuals who passed quality control (n ¼ 1006 cases and n ¼ 816 controls).

Statistical analyses
All analyses in the Norwegian cohort were performed using
the software packages PLINK version 1.07 [47] and R version
2.15.2 [48]. Quality control checks were performed with the
R software. For phenotyping and identification of covariates
the various birth-related outcomes were treated separately
for each pregnancy, whereas data regarding the total
obstetric history of a woman (including ever having had
a pregnancy resulting in a stillbirth) were treated as binary
variables. Longitudinal measures like BMI and BP were
averaged. Participants were classified as smokers if they
acknowledged to ever have smoked.
Variables associated with increased risk for developing
preeclampsia were examined against the main phenotype
preeclampsia in a generalized linear model (SDC5 Table 5,
Journal of Hypertension

http://links.lww.com/HJH/A681). Adjustment for smoking
as a risk factor was made based on whether participants
acknowledged having ever smoked (ever vs never smokers). Only those variables significantly associated with
the phenotype at P values 0.01 or less were incorporated
as covariates in the final model: maternal age, total number
of births per woman, average BMI at HUNT participation
of the woman, twin pregnancies, year of giving birth, and if
a woman had ever smoked (SDC5 Table 5, http://links.
lww.com/HJH/A681).
The associations between phenotypes and SNPs were
analyzed under an additive genetic model and tested in
a multiple logistic regression model with the PLINK software [47]. Statistical tests were two-sided, and associations
with a Bonferroni-corrected P value less than 0.05 for 119
independent tests (SNPs) (P < 0.00042) were considered
statistically significant.
We had 90% power to detect SNPs with an effect size
equivalent to odds ratio (OR) at least 1.6 with minor allele
frequency (MAF) 0.05, or OR at least 1.4 with MAF
0.10 under an additive model assuming a type 1 error rate
of 0.05 (adjusted for 119 SNP tests) and a two-sided test
(QUANTO power calculator [49], http://biostats.usc.edu/
Quanto.html).

The Australian preeclampsia genome-wide
association study
The preeclampsia GWAS in Australian samples has been
described in detail elsewhere [20,43]. Briefly, DNA was
extracted from the 1092 Australian case–control blood
samples using Qiagen’s Blood & Cell Culture DNA Midi
Kit (Qiagen Pty Ltd, Doncaster, Victoria, Australia) and
samples were genotyped on Illumina’s Human OmniExpress-12 BeadChip (Illumina Inc., San Diego, California,
USA). Quality control performance measures for individual
SNPs (genotype success rate, Hardy Weinberg equilibrium,
and minor allele copy number) and samples (genotype call
rate, random genotype error, and cryptic relatedness) were
conducted in PLINK [47]. Samples were excluded when
average call rates fell below 95%, where X chromosome
homozygosity rates were at least 0.2 (PLINK [47]), or if
estimates in PLINK indicated possible distant relations
between women in the cohort. The potential confounding
effect of population structure in the Australian preeclampsia GWAS cohort was negligible (genomic inflation
factor ¼ 1.002). Point-wise, asymptotic association tests
were performed in PLINK assuming an additive model of
gene action. The GWAS analyses included only SNPs passing genotyping and demonstrating call rates above 98%.

RESULTS
Descriptive characteristics of the selected study population
from HUNT (n ¼ 1822) are shown in Tables 1 and 2,
containing continuous and binary variables, respectively.
In the genetic association analysis, 1006 cases with preeclampsia and 816 controls with unaffected pregnancies
were included (SDC2 Table 2, http://links.lww.com/HJH/
A681). Significantly higher values were identified for preeclampsia cases compared with controls at time of
participation in HUNT for BMI (P < 0.001), weight
www.jhypertension.com
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TABLE 1. Continuous descriptive variables for the HUNT cohort included in the genotype-phenotype analyses
Descriptive variable

HUNT cohort (n ¼ 1822)

Cases (n ¼ 1006)

Controls (n ¼ 816)

Cases vs controls

Mean (SD)
Missing (n)
Mean (SD)
Missing (n)
Mean (SD)
Missing (n)
Birth year of participant
1956 (11.1)
0
1957 (10.5)
0
1955 (11.7)
0
BMI (kg/m2)c
26.5 (4.7)
1
27.3 (4.9)
0
25.6 (4.3)
0
Height (m2)c
165.4 (5.7)
0
165.3 (5.7)
0
165.5 (5.8)
0
Weight (kg)c
72.6 (13.5)
1
74.5 (14.1)
1
70.1 (12.3)
0
SBP (mmHg)c
128.1 (15.9)
0
131.0 (15.7)
1
124.4 (15.5)
0
DBP (mmHg)c
77.1 (9.8)
0
79.0 (9.6)
0
74.8 (9.7)
0
Age in years of mother at birth
23.3 (4.1)
123
23.6 (4.3)
71
22.8 (3.9)
52
of first child
Age in years of mother at birth
29.8 (5.0)
390
30.1 (4.7)
220
29.4 (5.3)
170
of last child
Waist circumference (cm)
86.05 (12.7)
50
87.67 (12.9)
26
84.05 (12.1)
24
Year of giving birthc
1984 (10.57)
0
1985 (10.24)
0
1984 (11.0)
0
Total number of birthsd
2.79 (median 3.0) (1.00)
0
2.85 (median 3.0) (0.96)
0
2.71 (median 3.0) (1.05)
0
Age in years of
26.9 (5.36)
0
27.0 (5.36)
0
26.7 (5.36)
0
mother at time of giving
birthc

P value
<0.01a
<0.001b
0.55a
<0.001b
<0.001b
<0.001b
<0.001a
<0.05a
<0.001b
<0.01a
<0.001a
<0.05b

Data collected at time of participation in HUNT irrespective of when the woman gave birth. HUNT, the HUNT Study; n, numbers.
a
Welch two sample t test.
b
Mann–Whitney U test.
c
Based on calculated averages for each individual according to all measurements given for the variable.
d
According to the latest information registered for the woman.

(P < 0.001), SBP and DBP (P < 0.001), diabetes of undefined type (P < 0.001), and waist circumference (P < 0.001)
(Table 1). In addition, cases had higher parity (P < 0.001)
and were younger at time of participation in HUNT when
compared with controls (Table 1). Finally, a significantly
higher percentage of the case women reported chronic
hypertension (P < 0.001), a diagnosis of diabetes mellitus
(P < 0.001), as well as a family history of hypertension
(P < 0.01) in the HUNT surveys. A higher proportion of
controls reported to ever have smoked compared with the
women who had experienced preeclampsia (P < 0.05)
(Table 2).
Of the 122 SNPs genotyped in the cohort, one SNP,
rs17367504, was significantly associated with preeclampsia
with the G (minor) allele demonstrating a protective effect
on disease development after correction for multiple testing
[P ¼ 3.52  105, OR 0.65, 95% confidence interval (CI)
0.53–0.80, allele frequency 13%]. The SNP rs17367504 is
located in intron 10 of the methylenetetrahydrofolate
reductase (MTHFR) gene on chromosome 1.
The top 10 association results for the preeclampsia
phenotype are given in Table 3, whereas a complete list
of association results for this trait can be found in Supporting information (SDC4 Table 4, http://links.lww.com/HJH/

A681). Three further SNPs demonstrated nominally
significant associations with preeclampsia: the intergenic
SNP rs17249754 located just downstream of the ATPase,
Ca2þ transporting, plasma membrane 1 (ATP2B1) gene
(P ¼ 0.02, OR 0.80, CI 95% 0.66–0.97), the intronic SNP
rs16933812 in the paired box 5 (PAX5) gene (P ¼ 0.04, OR
0.85, CI 95% 0.74–0.99), and the intronic SNP rs12946454,
located in the phospholipase C delta 3 gene (PLCD3)
(P ¼ 0.046, OR 0.85, CI 95% 0.73–0.80).
The top SNP (rs17367504) in our HUNT cohort was
successfully genotyped in the Australian preeclampsia
GWAS cohort but unlike in the HUNT cohort, the G-allele
was not associated with preeclampsia (P ¼ 0.68, OR 1.05,
95% CI 0.83–1.32, MAF ¼ 0.15). A possible risk for carriers
of the G-allele in the Australian cohort was not supported
by the CI.
A holistic examination of the associations with preeclampsia of the 122 SNPs previously demonstrating association with BP regulation or inflammation does not indicate
that using this selection strategy introduces an overall
enrichment for associations with preeclampsia. In fact,
we saw fewer significant associations than we would
have expected due to chance (SDC6 Fig. 1, http://links.
lww.com/HJH/A681).

TABLE 2. Binary descriptive variables for the HUNT cohort included in the genotype-phenotype analyses
Descriptive variable

HUNT cohort (n ¼ 1822)

Cases (n ¼ 1006)

Controls (n ¼ 816)

Cases vs controlsa

n (%)
754 (41.4)
221 (12.1)
821 (45.1)
483 (26.5)
278 (15.3)
674 (37.0)

n (%)
502 (49.9)
119 (11.8)
483 (48)
335 (33.3)
158 (15.7)
346 (34.4)

n (%)
252 (30.9)
102 (12.5)
338 (41.4)
148 (18.1)
120 (14.7)
328 (40.2)

P value
<0.001
0.70
<0.01
<0.001
0.62
<0.05

Chronic hypertension
Inflammatory diseaseb
Family history of hypertension
Diabetes (unspecified)
Smoking in pregnancy ever
Smoking ever

n, numbers.
a
Two-sample test for equality of proportions with continuity correction.
b
Includes rheumatoid arthritis, ankylosing spondylitis, psoriasis, psoriasis arthritis, and hyperthyroidism.
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TABLE 3. Top associations with preeclampsia after multiple logistic regression analysis
Rank

Chromosome

1
2
3
4
5

1
12
9
17
11

6
7
8
9
10

8
6
3
9
8

Gene
MTHFR
ATP2B1
PAX5
PLCD3
AX747213/ADAMTS8/
BC144419/BC144418
NOV
VEGFA/C6orf223
SLC4A7
TLR4/DBC1
ZFAT

Base pair

SNP

Effect allele

MAF

P value

11862778
90060586
36969205
43208121
130273230

a

OR (CI 95%)

rs17367504
rs17249754a
rs16933812a
rs12946454a
rs11222084a

G
A
G
T
T

0.130
0.146
0.338
0.255
0.349

3.52e  05
0.022
0.040
0.046
0.055

0.65
0.80
0.85
0.85
0.87

(0.53–0.80)
(0.66–0.97)
(0.74–0.99)
(0.73–0.80)
(0.75–1.00)

120353267
43951656
27537909
121278291
135567046

rs2469997a
rs910609b
rs13082711a
rs4132476b
rs1372662a

G
T
C
T
C

0.168
0.212
0.212
0.097
0.348

0.062
0.074
0.082
0.083
0.084

1.19
0.86
0.86
0.81
1.13

(0.99–1.43)
(0.72–1.02)
(0.72–1.02)
(0.64–1.03)
(0.98–1.30)

CI 95%, 95% confidence interval; MAF, minor allele frequency; OR, odds ratio; SNP, single nucleotide polymorphism.
a
Previously associated with blood pressure regulation.
b
Located to an inflammation gene.

DISCUSSION
Despite an increased focus on preeclampsia as a risk
factor for CVD development, few studies have investigated whether preeclampsia and CVD-related risk factors
share a genetic background. Here we have performed a
candidate SNP study in a preeclampsia-based cohort with
candidates selected at loci previously associated with BP
regulation and inflammation in GWAS. We identified one
intronic SNP, rs17367504, in the MTHFR gene in which
the G allele is significantly associated with a protective
effect on preeclampsia development in the HUNT cohort,
although not in the Australian cohort. The rs17367504 SNP
is located within the DNase1 hypersensitivity cluster in
125 cell types from the Encyclopedia of DNA Elements
and in a binding site for 16 transcription factors according
to the UCSC Genome Browser (http://genome.ucsc.edu/,
accessed 5 July 2015) [50]. Despite this strong evidence for
a regulatory role for this SNP, no significant expression
quantitative trait loci were found for rs17367504 in the
Genotype-Tissue Expression Project portal (http://gtexportal.org, accessed 5 July 2015) [51]. The G-allele of
this SNP has repeatedly been associated with lower SBP
as well as DBP in different ethnic populations [25,26], but
this is the first time this SNP has been associated
with preeclampsia.
The pleiotropic nature of the MTHFR gene is indicated
by more than 2900 publications on the term MTHFR gene.
Changes in the MTHFR gene have been indicated in
conditions such as hyperhomocysteinemia (a risk factor
for CVD), stroke, neural tube defects, cancer, and obstetric complications [38,52–54]. The MTHFR gene produces
the enzyme MTHFR, which converts 5,10-methylenetetrahydrofolate to 5-methyltetrahydrofolate, the active
form of folate. Connections between the folate cycle
and lipid metabolism have been demonstrated repeatedly
including that excess folate leads to reduced MTHFR
activity and increased lipogenesis [55], and that folate
deficiency is associated with elevated homocysteine due
to excess methionine scavenging by glycine N-methyltransferase, a key regulator of intracellular cholesterol
trafficking shown associated with increased risk for CVD
[56–58]. The similarities in preeclampsia and CVD pathophysiology support a role for MTHFR in preeclampsia,
but so far no studies have investigated the functional
Journal of Hypertension

implications of changes in rs17367504 in preeclampsia
or CVD.
The novel association suggested by our findings in the
HUNT cohort, between the BP-associated SNP rs17367504
and preeclampsia, adds to the increasing evidence that the
MTHFR gene influences the development of preeclampsia
and may point to a central role of the MTHFR gene in the
pathophysiology of both preeclampsia and chronic hypertension. Genetic studies of MTHFR in relation to development of preeclampsia, hypertensive gestational diseases, or
CVD have mainly investigated genetic associations with the
separate disorders, not focusing on possible pleiotropic
effects on both conditions. The preeclampsia studies conducted to date have largely focused on a missense MTHFR
SNP, rs1801133, and a regulatory MTHFR SNP, rs1801131
[38,59] and identified an association between the minor
alleles and an increased risk of preeclampsia. The MTHFR
SNP associated with preeclampsia in our HUNT cohort,
rs17367504, is not in linkage disequilibrium with either
of the two SNPs (rs1801133 and rs1801131, r2 < 0.5). Further, a recent study has identified the MTHFR gene promoter to be hypermethylated in placental tissue and
maternal blood of preeclamptic women [60].
Despite the increasing evidence from candidate gene
research and other genetic studies, no SNPs in the MTHFR
gene did reach genome-wide significance in the two GWAS
on preeclampsia reported to date [20,21]. In our study, the
top association from the HUNT Study was examined for
replication in the Australian GWAS cohort [20], resulting in a
nonsignificant finding not supporting the link between
preeclampsia and rs17367504 and rising the question about
a possible false positive finding. The lack of replication of
the association could also be due to the relatively small
sample size, which, coupled with the diagnostic and
genetic complexity of preeclampsia, leaves these studies
underpowered to detect SNPs with modest effect sizes. The
design of GWAS chips means that genotyped SNPs are
likely to tag causative variants rather than be functional
themselves, and different patterns of linkage disequilibrium
between populations means these associations may
weaken or disappear altogether. Indeed, both published
GWAS on preeclampsia were unable to replicate their
findings in independent cohorts [20,21]. To validate the
finding identified in the HUNT Study, further replication
www.jhypertension.com
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and functional studies on the SNP rs17367504 are required
in new preeclampsia cohorts.
The minor alleles of the three SNPs that were nominally
associated with a protective role against preeclampsia
development in our study have previously been associated
with BP regulation [25,26,28]. These SNPs are located in or
close to the ATP2B1, PAX5, and PLCD3 genes. Given the
nominal P values for association achieved by these variants
in this study, both further replication and molecular functional studies are warranted to identify a possible role as
disease modifiers in preeclampsia and CVD.
The main strength of this study is the deep phenotyping
including longitudinal variables that was performed on all
cases and controls. This might be one of the reasons why
we, in a cohort of this size, are able to identify a significant
association between preeclampsia and a genetic locus with
an acknowledged link to BP regulation. A weakness of the
present study is the lack of replication of the link between
preeclampsia and the SNP rs17367504 in an independent
preeclampsia cohort. Although nonsignificant, the G allele
in the Australian cohort did not demonstrate a trend toward
protection against preeclampsia, as identified in the HUNT
cohort. The result could have been strengthened further
had the result replicated in an independent preeclampsia
cohort. Further, the pleiotrophic effect of the SNP would
have been strengthened had the study aim included replication of the associations with BP regulation identified
through GWAS, but as the cohort was selected on the basis
of the preeclampsia diagnosis, not hypertension, the study
contained inadequate power for such a replication. A
relatively small number of women had developed chronic
hypertension at time of participation in HUNT, probably
because the preeclampsia cohort selected from HUNT
contained relatively young women (mean age 40.3 years
in HUNT2 and 52.1 years in HUNT3).
In summary, we have comprehensively assessed SNPs
previously reported to be associated with the phenotypes
BP regulation and inflammation for association with preeclampsia. Women who carry the G (minor) allele of the
intronic MTHFR SNP rs17367504 in the Norwegian HUNT
Study are significantly less prone to develop preeclampsia
than other women. Ours is the first study linking this BP
associated MTHFR SNP to preeclampsia, thereby identifying
a possible pleiotropic protective effect of the minor allele of
this variant on preeclampsia and hypertension. Further
genetic and functional studies in other cohorts are required
for validation of the association. Discovery of common
genetic associations between preeclampsia and hypertension will help identify shared etiological pathways.
Increased comprehension of pathophysiologic mechanisms may lead to improved screening for preeclampsia
and for subsequent risk of CVD.
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